Clinical Trials on Recurrent Liver Carcinoma

Total 38160 results

Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Sarcoma

United States
National Cancer Institute (NCI)

Terminated

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma... and other conditions

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Pulmonary Carcinoid Tumor

Canada
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary | Recurrent Oral Cavity... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the Gallbladder and other conditions

United States
UroGen Pharma Ltd.
Tanner Pharma Group

Available

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent
RenJi Hospital

Recruiting

Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence (HELP-2020)

Liver Transplant; Complications | Hepatocellular Carcinoma Recurrent

China
RenJi Hospital

Recruiting

Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant (PLENTY202001)

Liver Transplant; Complications | Hepatocellular Carcinoma Recurrent

China
University of Washington
National Cancer Institute (NCI)

Recruiting

Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Ovarian Epithelial Tumor

United States
National Cancer Institute (NCI)

Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma (IMMUNO-TH)

Liver Transplant | Hepatocellular Carcinoma Recurrent | Systemic Treatment
Medical University of Vienna

Completed

Efficacy of Edupression.Com® in Depressive Patients (eFICASY)

Depressive; Episode, Major | Recurrent Depressive Disorder, Current Episode Moderate | Recurrent Depressive Disorder, Current Episode Mild

Austria
Remix Therapeutics

Recruiting

Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma | Metastatic Adenoid Cystic Carcinoma | Recurrent Adenoid Cystic Carcinoma

United States
Verity Pharmaceuticals Inc.

Not yet recruiting

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (EVER)

Bladder Cancer | Urothelial Carcinoma Bladder | Bladder Cancer Recurrent | Neoplasm Recurrence | Urothelial Carcinoma Recurrent | Non-Invasive Bladder Urothelial Carcinoma
Hyunseok Kang, MD
NeoImmuneTech

Recruiting

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Resectable Oropharyngeal Squamous Cell Carcinoma

United States
Regeneron Pharmaceuticals
Sanofi

Completed

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

Recurrent Squamous Cell Carcinoma of Head | Recurrent Squamous Cell Carcinoma of Neck | Metastatic Squamous Cell Carcinoma of Head | Metastatic Squamous Cell Carcinoma Neck

Korea, Republic of, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Breast Carcinoma | Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Advanced Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Advanced Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States, Canada, Australia, Hong Kong, Korea, Republic of
University of Colorado, Denver

Active, not recruiting

Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma

Metastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell Carcinoma

United States
National Cancer Center, Japan
Merck Sharp & Dohme LLC

Recruiting

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) (Artemis)

Untreated Advanced or Recurrent Thymic Carcinomas

Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

Biochemically Recurrent Prostate Carcinoma

United States
Abbott

Terminated

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Liver Diseases | Digestive System Diseases | Neoplasms | Neoplasms by Histologic Type | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Digestive System Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | Hepatocellular Carcinoma Non-resectable | Hepatocellular Carcinoma...

United States, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Czech Republic, Denmark, Egypt, France, Germany, Greece, Hong Kong, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Norway, Puerto... and more
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Omega Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I)

Hepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-Resectable

United States, Hong Kong, Korea, Republic of, Singapore, Taiwan
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma

United States
Cliniques universitaires Saint-Luc- Université...

Terminated

Efficacy of SU 011248 in Head And Neck Carcinoma

Recurrent Disease | Squamous Cell Head and Neck Carcinoma | Palliative Treatment

France, Belgium
National Cancer Institute (NCI)

Active, not recruiting

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Cirrhosis | Hepatitis B Infection | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Recurrent Hepatocellular Carcinoma | Refractory Malignant Neoplasm | Hepatitis C Infection | Stage IV Hepatocellular Carcinoma AJCC v7

United States
Alpha Tau Medical LTD.

Recruiting

A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Recurrent Squamous Cell Carcinoma

United States, Israel
Second Military Medical University

Unknown

Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Recurrence Hepatocellular Carcinoma

China
National Cancer Institute (NCI)

Terminated

AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

IMC-A12 in Treating Patients With Advanced Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Patients With Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Metastatic Adenoid Cystic Carcinoma | Progressive Disease | Recurrent Adenoid Cystic Carcinoma

United States
National Cancer Institute (NCI)

Completed

Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States, Singapore
University of Washington
National Cancer Institute (NCI)

Terminated

Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Doxorubicin and Bortezomib in Treating Patients With Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States

Clinical Trials on Recurrent Liver Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations